Frontier Medicines News and Activities

View the org chart displaying its 26 main executives

Most searched biographies at Frontier Medicines

• Chris Varma, Chairman and Chief Executive Officer
• David Epstein, Director
• Cameron Wheeler, Director

Popular executive movements at Frontier Medicines

• Ryan McFadden has joined the company as Director, Medicinal Chemistry  (posted on April 17 2026).
• David Epstein has joined the company as Director  (posted on April 13 2026).

Create your alert
to follow the executive moves at Frontier Medicines.

Frontier Medicines has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).

Popular M&A news in Pharmaceuticals

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
• Hims & Hers has acquired Eucalyptus (posted on June 2 2026).

Popular contacts in Pharmaceuticals

• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• Richard Saynor - Chief Executive Officer at Sandoz
• Robert Ford - Chief Executive Officer and Chairman of the Board at Abbott

Learn more about the Pharmaceuticals industry

Press releases by Frontier Medicines

• Frontier Medicines Appoints Veteran Drug Development Leader David R. Epstein to Board of Directors | Frontier Medicines
• Frontier Medicines Announces Exclusive Licensing Agreement for FMC-220, a First-in-Class Covalent p53 Y220C Activator, with LG Chem, Ltd. | Frontier Medicines
• Frontier Medicines to Present Findings on PI3Kα-RAS Breaker FMC-242 and AI-Powered Frontier™ Platform at AACR Annual Meeting 2026 | Frontier Medicines
• Frontier Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference | Frontier Medicines
• Frontier Medicines Announces Publication in Nature Communications Highlighting a Novel Method that Enables Next-Generation Covalent Medicines | Frontier Medicines
• Frontier Medicines Announces Third Precision Oncology Development Candidate | Frontier Medicine
• Frontier Medicines Announces Publication in Structure Highlighting Novel E3 Ligase DCAF2 can be Harnessed for Targeted Protein Degradation | Frontier Medicine
• Frontier Medicines to Participate in September Investor Conferences | Frontier Medicine
• Frontier Medicines Unveils New Preclinical Data for FMC-220, a First-in-Class Covalent p53 Y220C Activator, at AACR 2025 | Frontier Medicine
• Frontier Medicines to Participate in Two Upcoming March Investor Conferences | Frontier Medicine
• View more press releases Close

Social media about Frontier Medicines

• Frontier Medicines on Wikipedia, Google News & Yahoo Finance
• Frontier Medicines on LinkedIn, X (Twitter) & YouTube